COVID-19

Achieve Life Sciences Announces Last Subject Last Visit Completed in Phase 2 ORCA-V1 Trial of Cytisinicline for e-Cigarette Cessation

Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...

Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19

FDA recommends additional revised primary symptom-based endpoints Revive to provide amended statistical analysis plan to support unblinding of the data...

89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology’s Annual Scientific Session Together with World Congress of Cardiology

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis to be Presented at the American Academy of Neurology 75th Annual Meeting

NEW YORK, March 03, 2023 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of data presentations highlighting data...

Microbot Medical Leverages Recently Awarded Non-Dilutive Grant from the Israeli Government to Promote Marketing Activities Toward Commercialization of the LIBERTY® Robotic System

Engagement with Interventional Radiologists Reaches Highest Level Yet as Company Continues to Progress Through Regulatory and Clinical Phases; Company Seeking...

error: Content is protected !!